Endo, Glaxo to Settle Suits Over Testosterone Drug
- Suits blame testosterone booster for causing heart attacks
- Accord follows Lilly’s decision to resolve testosterone cases
This article is for subscribers only.
Endo Pharmaceuticals Inc. and GlaxoSmithKline LLC agreed to settle lawsuits accusing the drugmakers of hiding the health risks of a testosterone-boosting drug marketed to middle-aged men, according to court filings.
The terms of the tentative deal weren’t disclosed Friday, but the accord would resolve more than 1,300 suits filed by men who blame a drug manufactured by Endo and co-promoted by GSK for causing potentially fatal blood clots. The settlement doesn’t cover cases targeting AbbVie Inc., one of the largest makers of testosterone-replacement medicines.